Sonova appoints Arnd Kaldowski as new CEO and successor of Lukas Braunschweiler

Sonova Holding AG, the world’s leading provider of hearing solutions, announces the retirement of CEO Lukas Braunschweiler after six years with the company and a total of fifteen years as a public company CEO. Arnd Kaldowski will initially join the Group as COO on October 1, 2017 and assume the CEO role after a transition phase on April 1, 2018. Arnd Kaldowski, a 50 year old German citizen, joins Sonova from Danaher Corporation, where he has served in various leadership capacities since 2008, most recently as Group Executive Diagnostics Platform and President Beckman Coulter Diagnostics.

In his initial role as COO, Arnd Kaldowski will have direct responsibility for all three businesses hearing instruments, retail and cochlear implants, as well as for research & development, supply chain and IT. Lukas Braunschweiler will continue to oversee finance, investor relations, human resources and communications. Arnd Kaldowski will assume responsibility for all functions and take over as CEO of Sonova on April 1, 2018. To further support the long-term continuity in the leadership of the company and to secure his extensive industry knowhow, the Board of Directors will propose Lukas Braunschweiler for election as a member of the Board of Directors of Sonova at the Annual General Shareholders’ Meeting in June 2018.

“With Arnd Kaldowski we have gained a proven and successful leader with a strong track record in the healthcare industry. Throughout his entire career, technology and innovation, digitalization and proximity to the customer were key,” says Robert Spoerry, Chairman of Sonova’s Board of Directors. “Arnd Kaldowski has led significant sales and productivity growth initiatives reflected in an impressive track record of M&A, commercial excellence and new product introduction,” adds Lukas Braunschweiler, CEO of Sonova.

 

In his most recent role as Group Executive Diagnostics Platform and President Beckman Coulter Diagnostics at Danaher Corporation, Arnd Kaldowski had overall revenue responsibility of USD 5.5 billion globally, including direct reporting of the operating companies Radiometer, Leica Biosystems and Cepheid, and including the Heads HR, legal, finance, business development (M&A), clinical affairs, regulatory and quality. Before joining Danaher, Arnd Kaldowski was SVP Point-of-Care Solutions at Siemens Medical, following his previous assignments as Investment Director of Atila Ventures and as Manager with the Boston Consulting Group.

 

Arnd Kaldowski holds a Master of Science in Physics from the Technical University Darmstadt, Germany, and an MBA from INSEAD in Fontainebleau, France. “Sonova is an exceptional high-tech company with strong Swiss roots in a very attractive growth market,” says Arnd Kaldowski. “I am excited about joining the very experienced Sonova management team and to contribute to the continuation of the Sonova success story.”

 

“Today, Sonova is in an excellent position,” concludes Robert Spoerry. “During his tenure Lukas Braunschweiler has helped to overcome various challenges quickly and subsequently grew the company together with his team by around 50% even in periods of substantial strengthening of the Swiss franc. This success was very much driven by a focused global growth and expansion strategy, a strong and unmatched technology pipeline and a second-to-none product portfolio. The well-proven and broad global leadership team of Sonova is poised to lead and expand the Group to the next level in terms of both size and market leadership.”

 

Disclaimer

 

This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Sonova’s control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sonova undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.